ROS1

ROS1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
Aliases ROS1, MCF3, ROS, c-ros-1, ROS proto-oncogene 1, receptor tyrosine kinase
External IDs MGI: 97999 HomoloGene: 2207 GeneCards: ROS1
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez

6098

19886

Ensembl

ENSG00000047936

ENSMUSG00000019893

UniProt

P08922

Q78DX7

RefSeq (mRNA)

NM_002944

NM_011282

RefSeq (protein)

NP_002935.2

NP_035412.2

Location (UCSC) Chr 6: 117.29 – 117.43 Mb Chr 10: 52.05 – 52.2 Mb
PubMed search [1] [2]
Wikidata
View/Edit HumanView/Edit Mouse

Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene.[3][4]

Function

This proto-oncogene, highly expressed in a variety of tumor cell lines, belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The protein encoded by this gene is a type I integral membrane protein with tyrosine kinase activity. The protein may function as a growth or differentiation factor receptor.[4]

Role in cancer

ROS1 is a receptor tyrosine kinase (encoded by the gene ROS1) with structural similarity to the anaplastic lymphoma kinase (ALK) protein; it is encoded by the c-ros oncogene and was first identified in 1986.[5][6][7][8] The exact role of the ROS1 protein in normal development, as well as its normal physiologic ligand, have not been defined.[6] Nonetheless, as gene rearrangement events involving ROS1 have been described in lung and other cancers, and since such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors, interest in identifying ROS1 rearrangements as a therapeutic target in cancer has been increasing.[5][9] Recently, the small molecule tyrosine kinase inhibitor, crizotinib, was approved for the treatment of patients with metastatic NSCLC whose tumors are ROS1 -positive.[10]

Gene rearrangements involving the ROS1 gene were first detected in glioblastoma tumors and cell lines.[11][12] In 2007 a ROS1 rearrangement was identified in a cell line derived from a lung adenocarcinoma patient.[13] Since that discovery, multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.[14][15][16] Clinical data supports the use of crizotinib in lung cancer patients with ROS1 gene fusions.[17][18] Preclinical and clinical work suggests multiple potential mechanisms of drug resistance in ROS1 + lung cancer, including kinase domain mutations in ROS1 and bypass signaling via RAS and EGFR.[19][20][21] Although the most preclinical and clinical studies of ROS1 gene fusions have been performed in lung cancer, ROS1 fusions have been detected in multiple other tumor histologies, including ovarian carcinoma, sarcoma, cholangiocarcinomas and others.[22] Crizotinib or other ROS1 inhibitors may be effective in other tumor histologies beyond lung cancer as demonstrated by a patient with an inflammatory myofibroblastic tumor harboring a ROS1 fusion with a dramatic response to crizotinib.[23]

Preclinical findings

From a large-scale survey of tyrosine kinase activity in non-small cell lung cancer (NSCLC), and identified more than 50 distinct tyrosine kinases and over 2500 downstream substrates, with the goal of identifying candidate oncogenes.[24] In a sampling of 96 tissue samples from NSCLC patients, approximately 30% displayed high levels of phosphotyrosine expression; further analysis was conducted to identify highly-phosphorylated tyrosine kinases in NSCLC from a panel of 41 NSCLC cell lines, and 150 patient samples.[24] Among the top 20 receptor tyrosine kinases identified in this analysis, 15 were identified in both cell lines and tumors, and among these were both ALK and [24] These initial findings paved the way for more expansive analyses of ROS1 kinase fusions in NSCLC and other cancers.

Fusion prevalence

In patients with NSCLC, approximately 2% are positive for a ROS1 gene rearrangement, and these rearrangements are mutually exclusive of ALK rearrangement.[25] ROS1 fusion-positive patients tend to be younger, with a median age of 49.8 years, and never-smokers, with a diagnosis of adenocarcinoma. There is a higher representation of Asian ethnicity and patients with Stage IV disease.[25] ROS1 rearrangements are estimated to be roughly half as common as ALK-rearranged NSCLCs. Similar to ALK-rearranged, ROS1-rearranged NSCLC have younger age of onset and a non-smoking history.[25] A benefit of a small-molecule ALK, ROS1 , and cMET inhibitor, crizotinib, was also shown in this patient group.

ROS1 expression was found in approximately 2% of NSCLC patients, and its expression was limited to those patients with ROS1 gene fusions.[9] Similar findings were reported in a separate analysis of 447 NSCLC samples, of which 1.2% were found to be positive for ROS1 rearrangement; this study also confirmed the activity of the ALK/ROS1 /cMET inhibitor crizotinib in ROS1 -positive tumors.[6] ROS1 fusions were also identified in approximately 2% of adenocarcinomas and 1% of glioblastoma samples in an assessment of kinase fusions across different cancers.[26]

Table 1: Sampling of ROS1 Rearrangements Observed in NSCLC and Other Cancers. All of the kinase fusions retain the tyrosine kinase domain of ROS1 . List is not exhaustive. (Adapted from Stumpfova 2012).

Cancer Type ROS1 Fusion Gene
NSCLC FIG - ROS1*; SLC34A2 - ROS1*; CD74 - ROS1*; SDC - ROS1*; EZR - ROS1; LRIG3 - ROS1; TPM3 - ROS1
Gastric SLC34A2 - ROS1*
Colorectal SLC34A2 - ROS1*
Spitzoid melanoma TPM3 - ROS1
Cholangiosarcoma FIG - ROS1*
Glioblastoma FIG - ROS1*
Ovarian FIG - ROS1*
Angiosarcoma CEP85L-ROS1

* Multiple variant isoforms observed

CD74; cluster of differentiation 74, long/short isoforms; EZR; ezrin; FIG; fused in glioblastoma; SDC4; LRIG3; leucine-rich repeats and immunoglobulin-like domains 3; SDC; syndecan 4; SLC34A2; solute carrier family 34 (sodium phosphate), member 2; TPM3; tropomyosin 3

As a drug target

References

  1. "Human PubMed Reference:".
  2. "Mouse PubMed Reference:".
  3. Galland F, Stefanova M, Lafage M, Birnbaum D (July 1992). "Localization of the 5' end of the MCF2 oncogene to human chromosome 15q15----q23". Cytogenetics and Cell Genetics. 60 (2): 114–6. doi:10.1159/000133316. PMID 1611909.
  4. 1 2 "Entrez Gene: ROS1 v-ros UR2 sarcoma virus oncogene homolog 1 (avian)".
  5. 1 2 Berge EM, Doebele RC (February 2014). "Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor". Seminars in Oncology. 41 (1): 110–25. doi:10.1053/j.seminoncol.2013.12.006. PMC 4159759Freely accessible. PMID 24565585.
  6. 1 2 3 Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC (September 2012). "Identifying and targeting ROS1 gene fusions in non-small cell lung cancer". Clinical Cancer Research. 18 (17): 4570–9. doi:10.1158/1078-0432.CCR-12-0550. PMC 3703205Freely accessible. PMID 22919003.
  7. Matsushime H, Wang LH, Shibuya M (August 1986). "Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule". Molecular and Cellular Biology. 6 (8): 3000–4. PMC 367872Freely accessible. PMID 3023956.
  8. Birchmeier C, Birnbaum D, Waitches G, Fasano O, Wigler M (September 1986). "Characterization of an activated human ros gene". Molecular and Cellular Biology. 6 (9): 3109–16. PMC 367045Freely accessible. PMID 3785223.
  9. 1 2 Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H (August 2012). "Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion". Clinical Cancer Research. 18 (16): 4449–57. doi:10.1158/1078-0432.CCR-11-3351. PMID 22661537.
  10. Berge EM, Doebele RC (February 2014). "Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor". Seminars in Oncology. 41 (1): 110–25. doi:10.1053/j.seminoncol.2013.12.006. PMC 4159759Freely accessible. PMID 24565585.
  11. Rabin M, Birnbaum D, Young D, Birchmeier C, Wigler M, Ruddle FH (July 1987). "Human ros1 and mas1 oncogenes located in regions of chromosome 6 associated with tumor-specific rearrangements". Oncogene Research. 1 (2): 169–78. PMID 3329713.
  12. Birchmeier C, Sharma S, Wigler M (December 1987). "Expression and rearrangement of the ROS1 gene in human glioblastoma cells". Proceedings of the National Academy of Sciences of the United States of America. 84 (24): 9270–4. doi:10.1073/pnas.84.24.9270. PMC 299735Freely accessible. PMID 2827175.
  13. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ (December 2007). "Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer". Cell. 131 (6): 1190–203. doi:10.1016/j.cell.2007.11.025. PMID 18083107.
  14. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y (March 2012). "RET, ROS1 and ALK fusions in lung cancer". Nature Medicine. 18 (3): 378–81. doi:10.1038/nm.2658. PMID 22327623.
  15. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ (March 2012). "ROS1 rearrangements define a unique molecular class of lung cancers". Journal of Clinical Oncology. 30 (8): 863–70. doi:10.1200/JCO.2011.35.6345. PMC 3295572Freely accessible. PMID 22215748.
  16. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC (September 2012). "Identifying and targeting ROS1 gene fusions in non-small cell lung cancer". Clinical Cancer Research. 18 (17): 4570–9. doi:10.1158/1078-0432.CCR-12-0550. PMC 3703205Freely accessible. PMID 22919003.
  17. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ (November 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer". The New England Journal of Medicine. 371 (21): 1963–71. doi:10.1056/NEJMoa1406766. PMID 25264305.
  18. Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O (March 2015). "Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort". Journal of Clinical Oncology. 33 (9): 992–9. doi:10.1200/JCO.2014.58.3302. PMID 25667280.
  19. Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT (June 2013). "Acquired resistance to crizotinib from a mutation in CD74-ROS1". The New England Journal of Medicine. 368 (25): 2395–401. doi:10.1056/NEJMoa1215530. PMID 23724914.
  20. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC (2013). "Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer". PloS One. 8 (12): e82236. doi:10.1371/journal.pone.0082236. PMC 3862576Freely accessible. PMID 24349229.
  21. Cargnelutti M, Corso S, Pergolizzi M, Mévellec L, Aisner DL, Dziadziuszko R, Varella-Garcia M, Comoglio PM, Doebele RC, Vialard J, Giordano S (March 2015). "Activation of RAS family members confers resistance to ROS1 targeting drugs". Oncotarget. 6 (7): 5182–94. doi:10.18632/oncotarget.3311. PMID 25691052.
  22. Davies KD, Doebele RC (August 2013). "Molecular pathways: ROS1 fusion proteins in cancer". Clinical Cancer Research. 19 (15): 4040–5. doi:10.1158/1078-0432.CCR-12-2851. PMID 23719267.
  23. Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM (August 2014). "Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions". Cancer Discovery. 4 (8): 889–95. doi:10.1158/2159-8290.CD-14-0377. PMID 24875859.
  24. 1 2 3 Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ (December 2007). "Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer". Cell. 131 (6): 1190–203. doi:10.1016/j.cell.2007.11.025. PMID 18083107.
  25. 1 2 3 Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ (March 2012). "ROS1 rearrangements define a unique molecular class of lung cancers". Journal of Clinical Oncology. 30 (8): 863–70. doi:10.1200/JCO.2011.35.6345. PMC 3295572Freely accessible. PMID 22215748.
  26. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C (2014-01-01). "The landscape of kinase fusions in cancer". Nature Communications. 5: 4846. doi:10.1038/ncomms5846. PMC 4175590Freely accessible. PMID 25204415.

Further reading

This article is issued from Wikipedia - version of the 11/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.